Why Repros Is Poised to Keep Plunging

Before you go, we thought you'd like these...
Before you go close icon

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage biotech company Repros Therapeutics has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Repros and see what CAPS investors are saying about the stock right now.

Reprosfacts

Headquarters (founded)

The Woodlands, Texas (1987)

Market Cap

$208.1 million

Industry

Pharmaceuticals

Trailing-12-Month EBITDA

($12.7 million)

Management

CEO Joseph Podolski (since 1992)
CFO Katherine Anderson (since 2011)

Trailing-12-Month Return on Equity

(69.9%)

Cash/Debt

$29.6 million / $0

Competitors

Abbott Labs
Auxilium Pharmaceuticals
Actavis


Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 54% of the 131 members who have rated Repros believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star TerryHogan, succinctly summed up the Repros bear case for our community:

They're burning through cash like a former child-star on a [V]egas bender, and they're handing out shares like they're breath mints at a halitosis convention. They have no revenues to speak of (in fact they don't have any revenue at all). And while the latest announcement about their clinical trial isn't exactly a nail in the coffin, it could be a sign of greater malfeasance.

If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Repros Is Poised to Keep Plunging originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners